CMV infection increases the risk of GvHD after bone marrow transplants.
47 citations
,
June 2013 in “Biology of blood and marrow transplantation” Mice with human fetal thymic tissue and stem cells developed symptoms similar to chronic graft-versus-host disease.
1 citations
,
November 2002 in “Journal of dermatology” The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.
Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.
January 2025 in “Case Reports in Hematology” Leukemia should be considered in teens with unexplained bleeding.
May 2014 in “Transfusion and Apheresis Science” The study found that the quality of cord blood units remains consistent before freezing and after thawing, indicating that attached tube segments reliably represent the graft's properties.
April 2026 in “Frontiers in Cell and Developmental Biology” CD200- cells in hair follicles have a higher ability to regenerate hair.
38 citations
,
January 2016 in “Cell Death and Disease” The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
13 citations
,
January 2010 in “PubMed” September 2021 in “Journal of the American Academy of Dermatology” CTCL patients can safely continue treatment during COVID-19 with proper safety measures.
November 2023 in “Journal of Investigative Dermatology” Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.
Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.
January 2026 in “Medicina” CD34 is absent in most basal cell carcinoma cells but present in surrounding skin.
9 citations
,
October 2008 in “British Journal of Dermatology” The growth of the Epstein-Barr virus in the patient's cells was linked to the worsening of her lymphoma.
A 72-year-old man was diagnosed with a rare skin form of Rosai-Dorfman disease after years of misdiagnosis.
28 citations
,
March 2010 in “Histochemistry and Cell Biology” Different markers are found in stem cells of the scalp's hair follicle bulge and the surrounding skin.
January 2012 in “heiDOK (Heidelberg University)” Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.
60 citations
,
October 2020 in “Nature Communications” AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.
6 citations
,
July 2019 in “Experimental Dermatology” Skin can produce blood cells, often due to disease, which might lead to new treatments for skin and blood conditions.
Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.
7 citations
,
February 2015 in “Journal of comparative pathology” CD8+ T cells play a key role in graft-versus-host disease in certain mice models.
January 2024 in “Wiadomości Lekarskie” DEC cells show promise as a safe and effective treatment for Duchenne muscular dystrophy.
105 citations
,
October 2018 in “Nature” A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
9 citations
,
February 2019 in “BMC cancer” M30 is a promising treatment for preventing hair loss during chemotherapy.
April 2017 in “Journal of Dermatological Science” B cells can both help and hinder the body's defense against melanoma.
15 citations
,
June 2019 in “Biochemical Journal” A new genetic disorder caused by an ODC1 mutation can be treated with DFMO.
July 2017 in “Cancer Research” Krt15+ cells in mice can resist radiation, regenerate tissue, and start tumors, suggesting new cancer treatment targets.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
4 citations
,
October 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.
22 citations
,
October 2000 in “British Journal of Haematology” Non-myeloablative stem cell transplants are a promising, less toxic option for older or weaker patients, with fewer side effects and good outcomes.